Germany’s Evotec Gets Takeover Interest From Halozyme

(Bloomberg) -- Germany’s Evotec SE is attracting potential takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc., people familiar with the matter said. Most Read from BloombergUnder Trump, Prepare for New US Transportation PrioritiesZimbabwe City of 700,000 at Risk of Running Dry by Year-EndSaudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency SaceNYC Congestion Pricing Plan With $9 Toll to Start in JanuaryThe Urban-Rural Divide Over Highway Expansion a